Watts Ryan J.'s Form 4 filing
Denali Therapeutics Inc. (DNLI) · filed Feb 11, 2022
- Accession no.
- 0001714899-22-000035
- Filed
- Feb 11, 2022
- Trade date
- Feb 9-10, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 2 derivative transactions. Open-market sales total $102.1K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Watts Ryan J.CIK 0001724310 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 9, 2022 | Common Stock | SSaleDisposed | −2,719 | $37.55F2 | −$102,098.45 | 2,119,442 | Indirect | |
| Feb 10, 2022 | Common Stock | MOption exerciseAcquired | +64,631 | $5.28 | +$341,251.68 | 254,522 | Direct | |
| Feb 10, 2022 | Common Stock | MOption exerciseAcquired | +6,118 | $9.60 | +$58,732.8 | 260,640 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 10, 2022 | Common Stock | MOption exerciseDisposed | −64,631 | $0.00 | $0 | 0 | Direct | |
| Feb 10, 2022 | Common Stock | MOption exerciseDisposed | −6,118 | $0.00 | $0 | 0 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $37.51 to $37.745 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.